OncoLink in English
Share
Recursos del Cáncer > Notícias sobre Cáncer > 2009 > octubre
IL-6 level predicts risk of hepatocellular carcinoma in women with HCV infection
Will Boggs, MD
Last Updated: 2009-10-30 13:30:02 -0400 (Reuters Health)
NEW YORK (Reuters Health) - Increasing levels of serum interleukin-6 are associated with a higher risk of hepatocellular carcinoma (HCC) in women infected with hepatitis C virus (HCV), say researchers from Japan in the November 15th International Journal of Cancer.
"Our study has shown that a higher serum IL-6 level is an independent risk factor for HCC development in female chronic hepatitis C patients," Dr. Hayato Nakagawa told Reuters Health. "This finding supports the important role of IL-6 signaling in hepatocarcinogenesis."
Dr. Nakagawa and colleagues at the University of Tokyo studied the association between serum IL-6 levels and the risk of hepatocarcinogenesis in 330 chronic hepatitis C patients.
Male and female patients had significantly higher IL-6 levels than did healthy controls, the authors report.
During an average follow-up of 9.0 years, 126 patients (4.2% per person-year) developed HCC. The cumulative incidence of HCC at 5 and 10 years was significantly higher in men than in women.
Among men, the cumulative incidence of HCC did not change significantly with rising serum IL-6 level, and serum IL-6 levels did not correlate significantly with any clinical characteristic.
In contrast, the cumulative incidence of HCC among women increased with rising serum IL-6 level, and serum IL-6 levels correlated significantly with serum transaminase levels.
"These results indicate that serum IL-6 is not merely a marker of liver inflammation, but represents a certain pathological process in hepatocarcinogenesis," Dr. Nakagawa explained. "IL-6 has already been a therapeutic target in rheumatoid arthritis and Castleman disease. It is a challenge for the future to investigate whether IL-6 will become a therapeutic target of HCC development."
"Although the serum IL-6 levels provide useful information on the risk of future HCC development in female hepatitis C patients, measurement of IL-6 is expensive," Dr. Nakagawa added. "We consider that it is too early to use it in the daily clinical practice. If the female patient with chronic hepatitis C has a higher serum IL-6 level, she should be carefully followed-up by monitoring tumor markers and ultrasonography every four to six months in accordance with the degree of liver fibrosis."
Int J Cancer 2009;125:2265-2269.
Copyright © 2010 Reuters Limited. All rights reserved.
Las traducciones de los artículos de noticias Reuters en la página Web OncoLink son hechas por un equipo de enfermeras de habla hispana con especialidad avanzada en oncología, y revisadas por médicos oncólogos de habla hispana, para asegurar precisión médica y sensibilidad cultural. Reuters no asume ningúna responsabilidad por las traducciones que son hechas por el equipo de traducción de OncoLink.